Sean Jochims
Pewaukee, WINPI 1861401473
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,137 and has fallen 69.3% since, to $349 in 2021.
Across 110 payments — averaging $19.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$360
- Novartis$212
- Acorda Therapeutics, Inc$166
- Teva Pharmaceuticals USA, Inc.$150
- AbbVie$129
- Eisai Inc.$125
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$563%
- Food & beverage$2,11497%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 31 | $360 |
| Novartis | 7 | $212 |
| Acorda Therapeutics, Inc | 4 | $166 |
| Teva Pharmaceuticals USA, Inc. | 5 | $150 |
| AbbVie(2 entities) | 7 | $129 |
| Eisai Inc. | 1 | $125 |
| Lundbeck LLC | 7 | $121 |
| AstraZeneca | 4 | $84 |
| Livanova USA, Inc. | 1 | $83 |
| Neurocrine Biosciences, Inc. | 5 | $76 |
| Biogen | 3 | $65 |
| Amgen | 3 | $62 |
| Jazz Pharmaceuticals Inc. | 4 | $62 |
| Amneal Pharmaceuticals LLC | 4 | $57 |
| Harmony Biosciences LLC | 2 | $56 |
| Lilly USA, LLC | 2 | $43 |
| Adamas Pharmaceuticals, Inc. | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| UCB, Inc. | 2 | $31 |
| Greenwich Biosciences, Inc. | 2 | $31 |
| MDD US Operations, LLC | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 2 | $27 |
| Upsher-smith Laboratories LLC | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Abbott | 1 | $20 |
| Bristol Myers Squibb | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.